Abstract
Municipal wastewater-based surveillance (WBS) programs for SARS-CoV-2 were valuable tools for epidemiological modelling and informing COVID-19 health policy during the pandemic. We conducted a “near to source” study to assess the capacity and performance of SARS-CoV-2 WBS programs in schools relative to municipal wastewater treatment plants (WWTP). Only 4/17 schools screened had plumbing systems that were amenable to WBS. From December 2020 - March 2021 composite wastewater collected 2X/week from four schools and three municipal WWTP were assessed for SARS-CoV-2 and fecal biomarkers. Schools had lower rates of successful sample collection relative to WWTP (44.7% vs 100%, p<0.001). In a time of low COVID-19 activity, 13/64 of school samples were positive of SARS-CoV-2-N1 vs 100% of WWTP. SARS-CoV-2-N1 detected in school wastewater associated with and preceded clinically identified infections, but did not correlate with rates of overall absenteeism. Notably levels of SARS-CoV-2-N1 and fecal biomarkers were markedly lower in wastewater from schools relative to WWTP. While our SARS-CoV-2 WBS program in schools did generate a leading signal relative to clinical disease, the significantly lower levels of SARS-CoV-2 and fecal biomarkers suggests that toileting habits of children who may avoid defecation at school adversely impact school-based WBS of targets shed in feces.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the Canadian Institute of Health Research and from Alberta Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted after receiving approval from the University of Calgary's Conjoint Health Research Ethics Board (REB20-1544).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.